Saturday 17 October 2026 Export OSUR’s income statement to Excel — free account

OraSure Technologies, Inc.

OSUR Healthcare Medical Instruments & Supplies

OraSure Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $115.0 million, down 38.1% from fiscal 2024. In the quarter to June 2026, revenue fell 1.93%, EPS grew 134.6%, free cash flow fell 1.40% and total debt fell 8.27%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.61 0.20 −5.25%

Follow OSUR

Alert me

Market cap: $262.8M
P/E: 0.0×
Fwd P/E: −3.9×
Dividend yield: —
F-score: 3/9
Altman Z: 1.47
Beneish M: −2.73
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.55

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	4	—	1	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 6.66%

Capital & Financial Ratios $m

Market Cap 262.77

Revenue 112.41

Net Income (49.13)

Free Cash Flow (48.83)

Net Debt (160.46)

Current Ratio 8.88

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (3.85)

P/S ratio 2.22

P/B ratio 0.78

Past 5Y EPS Growth —

This Y EPS Growth 29.79%

Next Y EPS Growth (22.73%)

Next Y revenue growth 6.15%

Next 5Y EPS Growth (27.98%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 39.40%

10-year low 10-year high

P/B against its own 10 years 20.20%

10-year low 10-year high

EV/Sales against its own 10 years 29.24%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	290	268	199	161
Receivables	40	24	22	27
Inventory	48	34	31	30
Other	2	3	4	2
	386	333	262	223

	2023	2024	2025	Q'26
Payables	13	8	7	8
ST’ Debt	—	—	—	—
Other	25	22	18	16
	40	33	40	25

Compound Annual Growth %

	10y	5y	3y
Sales	(0.40%)	(7.70%)	(33.29%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	7.89%	(3.08%)	(2.21%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	28	31	—	—	—
’25	30	31	27	27	115
’24	54	54	40	37	186
’23	155	85	89	76	405
’22	68	80	116	123	387
’21	59	58	54	64	234
’20	32	29	48	63	172

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(14)	(10)	—	—	—
’25	(20)	(10)	(10)	(9)	(49)
’24	7	8	13	0	27
’23	6	57	37	41	142
’22	(36)	(10)	16	(18)	(47)
’21	(4)	1	(19)	(13)	(35)
’20	2	(5)	4	4	6

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(15)	(12)	—	—	—
’25	(19)	(12)	(11)	(11)	(53)
’24	5	6	13	0	24
’23	5	52	35	40	131
’22	(84)	(21)	9	(15)	(111)
’21	(15)	(11)	(24)	(33)	(83)
’20	0	(8)	(1)	(12)	(23)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.32)	0.09	—	—	—
’25	(0.21)	(0.26)	(0.19)	(0.27)	(0.94)
’24	(0.05)	(0.01)	(0.06)	(0.14)	(0.26)
’23	0.37	(0.07)	0.15	0.27	0.72
’22	(0.28)	(0.26)	0.07	0.21	(0.25)
’21	0.05	(0.02)	(0.21)	(0.14)	(0.32)
’20	(0.12)	(0.16)	0.01	0.03	(0.22)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	5.09	8.39	10.27	6.35	5.23	8.25	2.62	4.38	3.52	2.08	Analyst estimates 2026–2028 Powerpack
	High	9.53	23.01	22.22	13.25	19.75	15.94	9.42	8.43	8.45	4.22
People
People	Employees	325	377	398	472	570	785	840	638	501	500
	Revenue/emp, $m	0.39	0.44	0.46	0.33	0.30	0.30	0.46	0.64	0.37	0.23
Income, $m
Income, $m	Revenue	128	167	182	155	172	234	387	405	186	115
	Gross margin, %	68.66	59.23	62.51	61.18	59.32	50.33	38.31	42.33	42.72	41.90
	EBT	20	41	32	21	(4)	(9)	(16)	56	(16)	(65)
	EBT margin, %	15.85	24.56	17.45	13.80	(2.05)	(3.98)	(4.05)	13.87	(8.61)	(56.15)
	Net income	20	31	20	17	(15)	(23)	(17)	54	(19)	(69)
	Depreciation	6	6	6	7	9	12	15	21	11	10
Per share, $
Per share, $	Revenue	2.31	2.83	2.97	2.51	2.54	3.25	5.34	5.53	2.50	1.57
	Earnings	0.35	0.52	0.33	0.27	(0.22)	(0.32)	(0.25)	0.73	(0.26)	(0.94)
	Cash flow	0.44	0.48	0.64	0.16	0.09	(0.49)	(0.65)	1.93	0.37	(0.67)
	Capex	(0.08)	(0.07)	(0.10)	(0.15)	(0.43)	(0.67)	(0.88)	(0.14)	(0.05)	(0.06)
	Free cash flow	0.36	0.40	0.54	0.01	(0.34)	(1.16)	(1.53)	1.79	0.32	(0.72)
	Book value	3.34	4.37	4.64	4.98	5.90	5.29	5.03	5.87	5.51	4.64
	Shares, m	56	59	61	62	68	72	73	73	74	73
Valuation, ×
Valuation, ×	P/E	25.11	36.40	34.35	29.74	0.00	0.00	0.00	11.50	0.00	0.00
	P/S	3.81	6.82	3.93	3.20	4.16	2.68	0.90	1.50	1.45	1.55
	P/B	2.63	4.41	2.52	1.61	1.79	1.64	0.95	1.41	0.65	0.52
	EV/Sales	2.87	5.89	3.07	2.20	2.95	2.03	0.61	0.78	0.01	(0.19)
	EV/FCF	18.17	41.28	17.02	694.46	(24.27)	(5.68)	(2.13)	2.42	0.04	0.40
Cash, $m
Cash, $m	Operating cash flow	25	28	39	10	6	(35)	(47)	142	27	(49)
	Capex	(4)	(4)	(6)	(9)	(29)	(48)	(64)	(10)	(4)	(4)
	Free cash flow	20	24	33	0	(23)	(83)	(111)	131	24	(53)
Balance, $m
Balance, $m	Working capital	139	190	191	192	242	231	256	347	300	222
	Total debt	—	—	—	1	1	2	1	0	0	0
	Net debt	(121)	(156)	(157)	(155)	(209)	(151)	(110)	(290)	(268)	(199)
	Shareholders’ equity	186	258	283	307	399	381	364	431	410	341
Returns, %
Returns, %	ROA	9.93	12.28	6.67	5.01	(3.71)	(5.02)	(3.79)	11.58	(4.05)	(15.57)
	ROIC	19.52	24.61	14.01	7.64	(1.70)	(2.77)	(5.45)	14.54	(12.37)	(31.75)
	ROE	11.42	13.94	7.53	5.64	(4.23)	(5.90)	(4.60)	13.50	(4.64)	(18.30)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ANGO AngioDynamics, Inc.	$487.0M	— (loss-making)	— (loss-making)	+6.87% (above 0%: growing)	n/m	+5.62% (above 0%: growing)	59.37%	(9.02%)	Compare
NNNN Anbio Biotechnology	$474.8M	—	—	—	—	—	—	—	Compare
EMBC Embecta Corp.	$365.5M	4.2×	3.8×	−8.05% (below 0%: shrinking)	−53.85% (below 0%: shrinking)	−49.63% (below 0%: shrinking)	56.42%	17.92%	Compare
ZJYL Jin Medical International Ltd.	$340.9M	—	—	—	—	−8,074.17% (below 0%: shrinking)	34.44%	0.00%	Compare
SMTI Sanara MedTech Inc.	$322.4M	— (loss-making)	125×	+9.04% (above 0%: growing)	n/m	+131.28% (above 0%: growing)	92.96%	6.33%	Compare
OSUR OraSure Technologies, Inc.	$262.8M	— (loss-making)	— (loss-making)	−1.93% (below 0%: shrinking)	n/m	−1.40% (below 0%: shrinking)	43.46%	17.76%
UTMD Utah Medical Products, Inc.	$237.8M	22.7×	28.7×	−14.31% (below 0%: shrinking)	−10.64% (below 0%: shrinking)	−55.74% (below 0%: shrinking)	55.79%	31.06%	Compare
PDEX Pro-Dex, Inc.	$194.1M	13.8×	23.5×	+16.65% (above 0%: growing)	+143.24% (above 0%: growing)	−78.95% (below 0%: shrinking)	34.75%	17.29%	Compare
KRMD KORU Medical Systems, Inc.	$139.9M	— (loss-making)	— (loss-making)	+18.15% (above 0%: growing)	n/m	+26.17% (above 0%: growing)	65.14%	5.21%	Compare
Median of peers	$331.7M	13.8×	26.1×	+7.96%	−10.64%	−49.63%	56.42%	6.33%

All 55 Medical Instruments & Supplies stocks →

OraSure Technologies, Inc. (OSUR) key facts

Concern: OraSure Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $115.0 million, down 38.1% from fiscal 2024.
OraSure Technologies, Inc. (OSUR) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, OSUR traded at $3.61, a market capitalization of $262.8 million.
Return on equity was −18.3% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 1.47 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.